Clinical Trials Logo

Filter by:
NCT ID: NCT02616536 Completed - Clinical trials for Educational Activities

Comparison Between Teaching Methods on Knowledge Gain of Physiotherapy Students

Start date: November 2015
Phase: N/A
Study type: Interventional

Procedures: The study will be conducted in two phases: Phase 1 - Perception and Satisfaction questionnaire will be developed - A validation test will be conducted on the Perception and Satisfaction questionnaire (face, content and construct) before conducting the study. The validation process will involve the participation of lecturers, professors and students by convenience sampling. Phase 2 - To prevent bias from the researchers, each participant will be given their code as their identification number. Then the participants will be randomly divided into two groups. They will be briefed on the purpose of study (stating that, the investigators would like to see the efficacy of various teaching methods on students' knowledge gain) and procedure of the study (examinations will be conducted, surveys at the end of each class session and at the end of the study). They are requested to fill up basic demographic data, consent form and ILS questionnaire(measuring the learning style of student) before beginning the study. - In this study, the lecture will be given by the 'Researcher 1' to standardize the input to the participants of the two groups. This will produce a standardized input to the students of the two groups of teaching method. - For the FC (flipped classroom) group, the length of the pre-recorded lecture videos will be the same which the participants can view it unlimitedly. An assignment will be given for FC group that will be attempted during the discussion class(2 hours) a week after with the lecturer. No grades will be given for the assignment. - Meanwhile for the TC(traditional classroom) group, a standard lecture class of 1 hour and 1 hour of tutorial class will be conducted on the same topic. The same ungraded assignment will also be given to this group a week after the lecture class to be attempted in the tutorial class - One day gap will be given following the discussion and tutorial class for FC and TC groups respectively following which an examination of 1 hour duration will be conducted to test on their level of knowledge (assessed by exam score) on the topic being taught for both the groups using the same set of questions. - At the end of the study, each participant will be given a feedback questionnaire to evaluate their perception and satisfaction on the teaching method applied on them using the 'Perception and Satisfaction Questionnaire'.

NCT ID: NCT02608073 Completed - Clinical trials for Nasopharyngeal Cancer

A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer

Start date: November 2004
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy, safety, tolerability, and effect on quality of life of oral capecitabine in combination with intravenous (IV) cisplatin in participants with metastatic nasopharyngeal cancer. Participants will receive up to 8 cycles of capecitabine treatment, and cisplatin will be administered on the first day of each cycle. The anticipated time on study treatment is up to 24 weeks, and the target sample size is 44 individuals.

NCT ID: NCT02604433 Completed - Beta-Thalassemia Clinical Trials

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia

BELIEVE
Start date: May 2, 2016
Phase: Phase 3
Study type: Interventional

This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) plus Best supportive care (BSC) versus placebo plus BSC in adults who require regular red blood cell transfusion due to (β)-thalassemia. The study is divided into the following periods: - Historical Period, - Screening/Run-in Period, - Double-blind Treatment Period (48 weeks), - Double-blind Long-term Treatment Period, (at the investigator's discretion an additional 48 weeks), - Open-Label Phase post unblinding and upon Data Monitoring Committee positive recommendation - Post-treatment Follow-up Period

NCT ID: NCT02597946 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

Afatinib in NSCLC With HER2 Mutation

Start date: March 18, 2016
Phase: Phase 2
Study type: Interventional

to investigate effectiveness and safety of afatinib in the advanced NSCLC patients with HER2 mutations, previously treated with 1 or 2 chemotherapy regimens

NCT ID: NCT02597933 Completed - Clinical trials for Scleroderma, Systemic

A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis

Start date: November 12, 2015
Phase: Phase 3
Study type: Interventional

Systemic Sclerosis (SSc) is a devastating disease of unknown etiology. Patients suffer from multiple organ fibrosis whereas lung fibrosis (interstitial lung disease, ILD) is one of the main driver for mortality. There is preclinical evidence for efficacy of nintedanib in SSc and associated ILD (SSc-ILD) and the anti-fibrotic efficacy of nintedanib was proven in idiopathic pulmonary fibrosis patients, who are presenting a similar pattern regarding lung fibrosis. Hence it is the purpose of the trial to confirm the efficacy and safety of nintedanib 150 mg bid in treating patients with SSc-ILD, compared with placebo. The trial will be conducted as a double blind, randomised, placebo-controlled trial with primary efficacy evaluation at week 52 and placebo-controlled treatment until last patient out (up to a maximum of 100 weeks). Respiratory function is globally accepted for assessment of treatment effects in patients with lung fibrosis. The chosen endpoint (Forced Vital Capacity (FVC) decline) is easy to obtain and is part of the usual examinations done in patients with SSc-ILD.

NCT ID: NCT02596230 Completed - Clinical trials for Venous Thromboembolism

RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism

Start date: November 5, 2015
Phase:
Study type: Observational

RE-COVERY is a large, multi-national, multi-center observational study based on new data collection. The study will enroll and characterize patients within 30 days of being diagnosed with an acute DVT and/or PE. The study has two main objectives. Objective 1 will characterize the DVT / PE patient population. All patients with a DVT and/or PE will be enrolled for cross-sectional characterization of the VTE patient population. Objective 2 will compare the safety and effectiveness of dabigatran etexilate regimens for treatment of VTE in comparison to VKA regimens. Patients treated with dabigatran etexilate or VKA will be followed up for the occurrence of outcome events for up to one year.

NCT ID: NCT02593396 Completed - Clinical trials for Hypoactive Sexual Desire Disorder

Bupropion in Sexual Dysfunction Among Methadone Maintenance Treatment Men

Start date: December 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the tolerability, safety, and efficacy of bupropion hydrochloride sustained-release in the treatment of sexual dysfunction in men on methadone maintenance therapy.

NCT ID: NCT02593214 Completed - Pregnancy Clinical Trials

Performance and Safety Trial of an Innovative Female Condom (Wondaleaf®)

Start date: August 2015
Phase: N/A
Study type: Interventional

General objective: To assess the performance and safety profile of a novel innovative design of female condom (Wondaleaf®) among healthy married women. Specific objectives : - To determine the failure rate of Wondaleaf®, in terms of clinical breakage, non-clinical breakage, invagination, misdirection, and slippage. - To determine the acceptability and satisfaction of use of Wondaleaf® by subjects and their spouses. - To assess the safety profile of Wondaleaf®.

NCT ID: NCT02588833 Completed - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.

PADDOCK
Start date: December 1, 2015
Phase: Phase 1
Study type: Interventional

The objectives of the study are to assess the safety, tolerability, preliminary efficacy and PK of multiple subcutaneous (SC) doses of pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria (PNH) who have not received treatment with eculizumab in the past. An exploratory objective of the study is to assess the pharmacodynamics (PD) of multiple SC doses of pegcetacoplan when administered to PNH patients.

NCT ID: NCT02587221 Completed - Influenza Clinical Trials

Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age

Start date: September 30, 2016
Phase: Phase 3
Study type: Interventional

A Phase III, Randomized, Observer-Blind, Controlled, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age.